Home » Stocks » IMPL

Impel NeuroPharma, Inc. (IMPL)

Stock Price: $13.97 USD 1.24 (9.74%)
Updated Jul 29, 2021 12:13 PM EDT - Market open
Market Cap 271.23M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 19.41M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $13.97
Previous Close $12.73
Change ($) 1.24
Change (%) 9.74%
Day's Open 12.89
Day's Range 12.63 - 14.20
Day's Volume 25,984
52-Week Range 6.90 - 15.89

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SEATTLE, July 07, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (Impel), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patien...

3 weeks ago - GlobeNewsWire

– Completed successful IPO raising approximately $80.0 million in gross proceeds – – NDA for TRUDHESA for treatment of acute migraine accepted for review by FDA; PDUFA date of September 6, 2021 – – Stre...

1 month ago - GlobeNewsWire

Initiative Features Artwork from Internationally Renowned Artist Ed Fairburn, Specially Developed to Illustrate the Complexities of Migraine Initiative Features Artwork from Internationally Renowned Art...

2 months ago - GlobeNewsWire

The news: Seattle-based biotech company Impel NeuroPharma raised $80 million in its initial public offering and will begin trading on the NASDAQ Friday.

3 months ago - GeekWire

SEATTLE, April 22, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (Impel), a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformati...

3 months ago - GlobeNewsWire

Impel NeuroPharma has filed to raise $75 million in an IPO to bring a migraine drug to market. The candidate, Trudhesa, is delivered using a metered dose device intended to get the active ingredient int...

3 months ago - FiercePharma

Impel NeuroPharma, Inc. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC

Veeva (VEEV) collaborates with Impel to accelerate the pre-launch planning and digital-first commercial execution for migraine treatment.

4 months ago - Zacks Equity Research

About IMPL

Impel NeuroPharma is a late-stage pharmaceutical company focused on utilizing our proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system, or CNS. We have designed our proprietary Precision Olfactory Delivery, or POD, upper nasal delivery technology to target the vascular-rich upper nasal cavity, and to provide rapid absorption, consistent drug biodistribution and ease of use for a patient, pro... [Read more...]

Industry
Biotechnology
IPO Date
Apr 23, 2021
CEO
Michael Hite
Employees
59
Stock Exchange
NASDAQ
Ticker Symbol
IMPL
Full Company Profile

Financial Performance

Financial Statements